Efficacy and safety of apatinib with or without radiotherapy as second-line or beyond therapy in patients with advanced/recurrent esophageal squamous cell carcinoma
第一作者机构：[1]Univ Elect Sci & Technol China, Sch Med, Sichuan Canc Hosp & Inst, Dept Radiat Oncol,Sichuan Canc Ctr, Chengdu, Peoples R China[2]Sichuan Canc Hosp, Chengdu, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Lv Jiahua,Li Tao,Wang Qifeng,et al.Efficacy and safety of apatinib with or without radiotherapy as second-line or beyond therapy in patients with advanced/recurrent esophageal squamous cell carcinoma[J].JOURNAL OF CLINICAL ONCOLOGY.2018,36(15):E33-E34.doi:10.1200/JCO.2018.36.15_suppl.e16044.
APA：
Lv, Jiahua,Li, Tao,Wang, Qifeng,Fan, Yu,Wang, Junchao&Lang, Jinyi.(2018).Efficacy and safety of apatinib with or without radiotherapy as second-line or beyond therapy in patients with advanced/recurrent esophageal squamous cell carcinoma.JOURNAL OF CLINICAL ONCOLOGY,36,(15)
MLA：
Lv, Jiahua,et al."Efficacy and safety of apatinib with or without radiotherapy as second-line or beyond therapy in patients with advanced/recurrent esophageal squamous cell carcinoma".JOURNAL OF CLINICAL ONCOLOGY 36..15(2018):E33-E34
医学